<DOC>
	<DOCNO>NCT00582140</DOCNO>
	<brief_summary>The investigator try find new method treat prostate cancer . The approach investigator take try enhance patient immune response cancer . In study investigator test safety vaccine may able help body fight prostate cancer .</brief_summary>
	<brief_title>Prostatic Acid Phosphatase ( PAP ) Vaccine Patients With Prostate Cancer</brief_title>
	<detailed_description>The purpose research determine safety serial intradermal vaccination DNA vaccine encode human PAP , GM-CSF vaccine adjuvant , subject stage D0 prostate cancer . In addition , determine whether PAP-specific IFNÐ£-secreting CD8+ T cell augment subject stage D0 prostate cancer mean immunization plasmid DNA vaccine encode PAP . This phase I design patient receive vaccine pTVG-HP rhGM-CSF administer i.d . biweekly 6 total dos . There three escalate dose cohort . The dose cohort consider maximum tolerate dose level expand total 16 patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Must histologic diagnosis adenocarcinoma prostate Must complete local therapy surgery and/or ablative radiation therapy least 2 month prior entry . Must clinical stage D0 disease define follow : In patient treat surgery , serum PSA value must &gt; 2 ng/ml two measurement least two week apart . In patient treated ablative radiation therapy , three consecutive increase serum PSA must document , least one month interval value finalPSA &gt; 2ng/ml . Prior history second malignancy allow treated curative intent disease free &gt; 5 year . Karnofsky performance score &gt; 70 No evidence immunosuppression treat immunosuppressive therapy , chemotherapy , chronic treatment dose corticosteroid ( great equivalent 10 mg prednisone per day ) , radiation therapy &gt; 30 % bone marrow , within 6 month first vaccination . Must concurrent androgen ablative ( hormonal ) therapy , must complete therapy least one month prior study entry . Must demonstrate PSA progression prior hormonal therapy chemotherapy . Must know evidence bone metastases nonregional lymph node involvement ( stage D2 disease ) determine bone scan CT scan . Must treat previously another investigational anti tumor vaccine .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Stage D0</keyword>
	<keyword>Non-Metastatic</keyword>
	<keyword>Rising PSA</keyword>
</DOC>